[1]贾晓兰,陆骏麒,彭志佳.眼底激光单用和联合雷珠单抗治疗糖尿病性视网膜病变患者的疗效观察[J].医学信息,2023,36(09):94-97.[doi:10.3969/j.issn.1006-1959.2023.09.018]
　JIA Xiao-lan,LU Jun-qi,PENG Zhi-jia.Observation on the Curative Effect of Fundus Laser Alone and Combined with Ranibizumab in the Treatment of Patients with Diabetic Retinopathy[J].Journal of Medical Information,2023,36(09):94-97.[doi:10.3969/j.issn.1006-1959.2023.09.018]
点击复制

眼底激光单用和联合雷珠单抗治疗糖尿病性视网膜病变患者的疗效观察()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年09期
页码:
94-97
栏目:
论著
出版日期:
2023-05-01

文章信息/Info

Title:
Observation on the Curative Effect of Fundus Laser Alone and Combined with Ranibizumab in the Treatment of Patients with Diabetic Retinopathy
文章编号:
1006-1959（2023）09-0094-04
作者:
贾晓兰; 陆骏麒; 彭志佳
（常熟市中医院眼科，江苏 常熟 215500）
Author(s):
JIA Xiao-lan; LU Jun-qi; PENG Zhi-jia
(Department of Ophthalmology,Changshu City Hospital of Traditional Chinese Medicine,Changshu 215500,Jiangsu,China)
关键词:
糖尿病性视网膜病变; 视网膜激光光凝术; 雷珠单抗; 最佳矫正视力; 黄斑中心凹厚度
Keywords:
Diabetic retinopathy; Retinal laser photocoagulation; Ranibizumab; Best corrected visual acuity; Macular foveal thickness
分类号:
R774.1；R587.2
DOI:
10.3969/j.issn.1006-1959.2023.09.018
文献标志码:
A
摘要:
目的 观察眼底激光单用与联合雷珠单抗治疗糖尿病性视网膜病变（DR）患者的疗效。方法 以2020年8月-2022年3月常熟市中医院收治的60例DR患者为研究对象，采用随机数字表法分为对照组（30例）与观察组（30例），对照组单用眼底激光治疗（视网膜激光光凝术），观察组在其基础上联合雷珠单抗治疗。比较两组临床疗效（治疗后1个月）、最佳矫正视力（BCVA）、黄斑中心凹厚度（CMT）、视神经纤维层厚度（颞下方、鼻侧、颞上方）、并发症。结果 观察组眼底出血、渗出吸收有效率高于对照组（P＜0.05）；治疗后1个月，观察组BCVA高于对照组，CMT小于对照组（P＜0.05）；观察组治疗后1个月视神经纤维层厚度（颞下方、鼻侧、颞上方）大于对照组（P＜0.05）；观察组并发症发生率小于对照组（P＜0.05）。结论 眼底激光联合雷珠单抗治疗DR疗效确切，可提高眼底出血、渗出的吸收效果，改善患者视力及视神经纤维层厚度，削减黄斑中心凹视网膜厚度，其效果优于单纯眼底激光治疗，且并发症少，安全性高。
Abstract:
Objective To observe the efficacy of fundus laser alone and combined with ranibizumab in the treatment of patients with diabetic retinopathy (DR).Methods From August 2020 to March 2022, 60 patients with DR admitted to Changshu City Hospital of Traditional Chinese Medicine were selected as the research objects. They were divided into control group (30 cases) and observation group (30 cases) by random number table method. The control group was treated with fundus laser (retinal laser photocoagulation), and the observation group was treated with ranibizumab on the basis of the control group. The clinical efficacy (1 month after treatment), best corrected visual acuity (BCVA), central macular thickness (CMT), optic nerve fiber layer thickness (inferior temporal, nasal, superior temporal) and complications were compared between the two groups.Results The effective rate of fundus hemorrhage and exudation absorption in the observation group was higher than that in the control group (P<0.05). One month after treatment, BCVA in the observation group was higher than that in the control group, and CMT was lower than that in the control group (P<0.05). One month after treatment, the thickness of optic nerve fiber layer (inferior temporal, nasal and superior temporal) in the observation group was greater than that in the control group (P<0.05). The incidence of complications in the observation group was lower than that in the control group (P<0.05).Conclusion Fundus laser combined with ranibizumab is effective in the treatment of DR, which can improve the absorption effect of fundus hemorrhage and exudation, improve the visual acuity and the thickness of optic nerve fiber layer, and reduce the thickness of macular fovea retina. The effect is better than that of fundus laser alone, with fewer complications and high safety.

参考文献/References:

[1]林翎,卢毓敏,马胜生.雷珠单抗联合眼底激光治疗糖尿病视网膜病变的疗效[J].实用医学杂志,2021,37(20):2660-2664.[2]Torp TL,Kawasaki R,Wong TY,et al.Temporal changes in retinal vascular parameters associated with successful panretinal photocoagulation in proliferative diabetic retinopathy: A prospective clinical interventional study[J].Acta Ophthalmologica,2018,96(4):405-410.[3]张媛.视网膜激光光凝治疗增殖性糖尿病视网膜病变的疗效[J].中国激光医学杂志,2018,27(2):149.[4]张斌,孙先勇.全视网膜激光光凝术联合药物治疗严重糖尿病视网膜病变疗效观察[J].陕西医学杂志,2017,46(10):1440-1441.[5]朱兆锋,李旭辉,张康玉,等.雷珠单抗联合眼底激光治疗DR患者的效果及对术后生活质量、视膜网微循环影响[J].湖南师范大学学报(医学版),2021,18(1):115-117.[6]张永红,张晓湄,付鹏.玻璃体腔注射雷珠单抗对增殖性糖尿病视网膜病变患者手术后视力的影响[J].河北医学,2017,23(7):1105-1108.[7]中华医学会眼科学会眼底病学组.我国糖尿病视网膜病变临床诊疗指南(2014年)[J].中华眼科杂志,2014,50(11):851-865.[8]钟志伟,邵东平.玻璃体腔注射雷珠单抗联合全视网膜光凝及单纯全视网膜光凝治疗高危增殖性糖尿病视网膜病变的对比研究[J].海南医学,2019,30(11):1401-1403.[9]齐艳秀,宿星杰,张剑,等.雷珠单抗治疗糖尿病视网膜病变玻璃体出血患者的疗效分析[J].中国现代医学杂志,2019,29(2):50-53.[10]文勇,李蓓.全视网膜激光光凝治疗糖尿病视网膜病变的前瞻性研究[J].中国临床医生杂志,2021,49(4):493-496.[11]余艳曙,陈辉,徐珂晨,等.雷珠单抗辅助玻璃体切割对增殖性糖尿病视网膜病变患者眼功能的影响[J].中华全科医学,2019,17(1):80-82.[12]徐冰,史喜红,白雪.眼底激光联合雷珠单抗对糖尿病视网膜病变及静脉阻塞引起黄斑水肿患者视力情况的影响研究[J].检验医学与临床,2022,19(7):962-964.[13]贺兵,赵学章.激光光凝治疗糖尿病视网膜病变的疗效观察[J].实用医院临床杂志,2018,15(5):164-166.[14]Vergmann AS,Nguyen TT,Torp TL,et al.Efficacy and Side Effects of Individualized Panretinal Photocoagulation[J].Ophthalmology Retina,2020,4(6):642-644.[15]王志玉,史爱云.雷珠单抗联合全视网膜激光光凝治疗重度非增生型糖尿病视网膜病变的疗效观察[J].眼科新进展,2017,37(8):776-779,784.[16]Mehanna CJ,Fattah MA,Haddad S,et al.Anti-VEGF Therapy for Persistent Neovascularization after Complete Panretinal Photocoagulation in Proliferative Diabetic Retinopathy[J].Ophthalmology Retina,2019,3(6):473-477.[17]周磊,赵中芳,杜改萍.抗VEGF药物联合全视网膜光凝治疗糖尿病视网膜病变的疗效及预后[J].中国激光医学杂志,2019,28(4):203-208.[18]Lang GE,Stahl A,Voegeler J,et al.Observational outcomes in proliferative diabetic retinopathy patients following treatment with ranibizumab, panretinal laser photocoagulation or combination therapy - The non-interventional second year follow-up to the PRIDE study[J].Acta Ophthalmologica,2022,100(2):e578-e587.[19]Murtaza S,Saim KM,Ahsan M,et al.Efficacy of intravitreal bevacizumab combined with pan retinal photocoagulation versus panretinal photocoagulation alone in treatment of proliferative diabetic retinopathy[J].Pakistan Journal of Medical Sciences,2017,33(1):142-145.[20]陈圣文,吴子东,李刚.雷珠单抗玻璃体腔注射联合激光与单纯激光治疗糖尿病视网膜病变在视力恢复中的效果比较[J].临床和实验医学杂志,2017,16(18):1800-1802.[21]Roy S,Kern TS,Song B,et al.Mechanistic Insights into Pathological Changes in the Diabetic Retina: Implications for Targeting Diabetic Retinopathy[J].Am J Pathol,2017,187(1):9-19.[22]Jampol LM,Odia I,Glassman AR,et al.Panretinal Photocoagulation vs Ranibizumab for Proliferative Diabetic Retinopathy: Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness in a Randomized Clinical Trial[J].Retina,2019,39(1):69-78.

相似文献/References:

[1]范 虹.糖尿病性视网膜病变患者血清VEGF、ES、TSP水平与眼底病变的相关性[J].医学信息,2021,34(09):119.[doi:10.3969/j.issn.1006-1959.2021.09.031]
　FAN Hong.Correlation Between Serum VEGF,ES,TSP Levels and Fundus Pathology in Patients with Diabetic Retinopathy[J].Journal of Medical Information,2021,34(09):119.[doi:10.3969/j.issn.1006-1959.2021.09.031]
[2]焦 聪,李 蓉,姚国敏,等.全科医疗在糖尿病性视网膜病变患者管理中的应用[J].医学信息,2022,35(15):171.[doi:10.3969/j.issn.1006-1959.2022.15.041]
　JIAO Cong,LI Rong,YAO Guo-min,et al.Application of General Practice in the Management of Patients with Diabetic Retinopathy[J].Journal of Medical Information,2022,35(09):171.[doi:10.3969/j.issn.1006-1959.2022.15.041]
[3]李 盈,李 涛,王 潇,等.利用SPECT影像技术评估糖尿病视网膜病变与糖尿病肾病的相关性[J].医学信息,2024,37(05):108.[doi:10.3969/j.issn.1006-1959.2024.05.018]
　LI Ying,LI Tao,WANG Xiao,et al.Correlation Between Diabetic Retinopathy and Diabetic Nephropathy by SPECT Imaging Technique[J].Journal of Medical Information,2024,37(09):108.[doi:10.3969/j.issn.1006-1959.2024.05.018]

更新日期/Last Update: 1900-01-01